Cardiovascular  ||| S:0 E:15 ||| JJ
risk  ||| S:15 E:20 ||| NN
in  ||| S:20 E:23 ||| IN
women  ||| S:23 E:29 ||| NNS
attending  ||| S:29 E:39 ||| VBG
primary  ||| S:39 E:47 ||| JJ
care  ||| S:47 E:52 ||| NN
centres ||| S:52 E:59 ||| NNS
:  ||| S:59 E:61 ||| :
baseline  ||| S:61 E:70 ||| JJ
data  ||| S:70 E:75 ||| NNS
of  ||| S:75 E:78 ||| IN
the  ||| S:78 E:82 ||| DT
EVA  ||| S:82 E:86 ||| NNP
study  ||| S:86 E:92 ||| NN
The  ||| S:92 E:96 ||| DT
purpose  ||| S:96 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
this  ||| S:107 E:112 ||| DT
study  ||| S:112 E:118 ||| NN
was  ||| S:118 E:122 ||| VBD
to  ||| S:122 E:125 ||| TO
determine  ||| S:125 E:135 ||| VB
the  ||| S:135 E:139 ||| DT
prevalence  ||| S:139 E:150 ||| NN
of  ||| S:150 E:153 ||| IN
hypertension ||| S:153 E:165 ||| NN
,  ||| S:165 E:167 ||| ,
cardiovascular  ||| S:167 E:182 ||| JJ
risk  ||| S:182 E:187 ||| NN
factors  ||| S:187 E:195 ||| NNS
and  ||| S:195 E:199 ||| CC
target  ||| S:199 E:206 ||| NN
organ  ||| S:206 E:212 ||| NN
damage  ||| S:212 E:219 ||| NN
using  ||| S:219 E:225 ||| VBG
baseline  ||| S:225 E:234 ||| NN
data  ||| S:234 E:239 ||| NNS
from  ||| S:239 E:244 ||| IN
the  ||| S:244 E:248 ||| DT
EVA  ||| S:248 E:252 ||| NNP
study ||| S:252 E:257 ||| NN
.  ||| S:257 E:259 ||| .
EVA  ||| S:259 E:263 ||| NNP
is  ||| S:263 E:266 ||| VBZ
a  ||| S:266 E:268 ||| DT
5-year  ||| S:268 E:275 ||| JJ
multicentre  ||| S:275 E:287 ||| JJ
prospective  ||| S:287 E:299 ||| JJ
study  ||| S:299 E:305 ||| NN
of  ||| S:305 E:308 ||| IN
women  ||| S:308 E:314 ||| NNS
aged  ||| S:314 E:319 ||| VBN
between  ||| S:319 E:327 ||| IN
40  ||| S:327 E:330 ||| CD
and  ||| S:330 E:334 ||| CC
70  ||| S:334 E:337 ||| CD
years  ||| S:337 E:343 ||| NNS
attending  ||| S:343 E:353 ||| VBG
primary  ||| S:353 E:361 ||| JJ
care  ||| S:361 E:366 ||| NN
centres  ||| S:366 E:374 ||| NN
in  ||| S:374 E:377 ||| IN
a  ||| S:377 E:379 ||| DT
rural-urban  ||| S:379 E:391 ||| JJ
area  ||| S:391 E:396 ||| NN
in  ||| S:396 E:399 ||| IN
the  ||| S:399 E:403 ||| DT
north  ||| S:403 E:409 ||| NN
of  ||| S:409 E:412 ||| IN
Spain ||| S:412 E:417 ||| NNP
.  ||| S:417 E:419 ||| .
The  ||| S:419 E:423 ||| DT
recruitment  ||| S:423 E:435 ||| JJ
period  ||| S:435 E:442 ||| NN
was  ||| S:442 E:446 ||| VBD
between  ||| S:446 E:454 ||| IN
October  ||| S:454 E:462 ||| NNP
2009  ||| S:462 E:467 ||| CD
and  ||| S:467 E:471 ||| CC
January  ||| S:471 E:479 ||| NNP
2010 ||| S:479 E:483 ||| CD
.  ||| S:483 E:485 ||| .
The  ||| S:485 E:489 ||| DT
following  ||| S:489 E:499 ||| JJ
variables  ||| S:499 E:509 ||| NNS
were  ||| S:509 E:514 ||| VBD
analysed ||| S:514 E:522 ||| VBN
:  ||| S:522 E:524 ||| :
associated  ||| S:524 E:535 ||| VBN
cardiovascular  ||| S:535 E:550 ||| JJ
risk  ||| S:550 E:555 ||| NN
factors ||| S:555 E:562 ||| NNS
,  ||| S:562 E:564 ||| ,
target  ||| S:564 E:571 ||| NN
organ  ||| S:571 E:577 ||| NN
damage  ||| S:577 E:584 ||| NN
and  ||| S:584 E:588 ||| CC
cardiovascular  ||| S:588 E:603 ||| JJ
or  ||| S:603 E:606 ||| CC
renal  ||| S:606 E:612 ||| JJ
disease  ||| S:612 E:620 ||| NN
defined  ||| S:620 E:628 ||| VBN
according  ||| S:628 E:638 ||| VBG
to  ||| S:638 E:641 ||| TO
the  ||| S:641 E:645 ||| DT
2007  ||| S:645 E:650 ||| CD
European  ||| S:650 E:659 ||| JJ
Society  ||| S:659 E:667 ||| NNP
of  ||| S:667 E:670 ||| IN
Hypertension  ||| S:670 E:683 ||| NNP
and  ||| S:683 E:687 ||| CC
the  ||| S:687 E:691 ||| DT
European  ||| S:691 E:700 ||| NNP
Society  ||| S:700 E:708 ||| NNP
of  ||| S:708 E:711 ||| IN
Cardiology  ||| S:711 E:722 ||| NNP
Guidelines  ||| S:722 E:733 ||| NNP
( ||| S:733 E:734 ||| -LRB-
2007  ||| S:734 E:739 ||| CD
ESH ||| S:739 E:742 ||| NNP
/ ||| S:742 E:743 ||| NNP
ESC  ||| S:743 E:747 ||| NNP
2007 ||| S:747 E:751 ||| CD
) ||| S:751 E:752 ||| -RRB-
.  ||| S:752 E:754 ||| .
Blood  ||| S:754 E:760 ||| NN
pressure  ||| S:760 E:769 ||| NN
< ||| S:769 E:770 ||| SYM
140 ||| S:770 E:773 ||| CD
/ ||| S:773 E:774 ||| CD
90  ||| S:774 E:777 ||| CD
mmHg  ||| S:777 E:782 ||| JJ
and  ||| S:782 E:786 ||| CC
< ||| S:786 E:787 ||| SYM
130 ||| S:787 E:790 ||| CD
/ ||| S:790 E:791 ||| CD
80  ||| S:791 E:794 ||| CD
in  ||| S:794 E:797 ||| IN
diabetics  ||| S:797 E:807 ||| NNS
were  ||| S:807 E:812 ||| VBD
considered  ||| S:812 E:823 ||| VBN
target  ||| S:823 E:830 ||| NN
blood  ||| S:830 E:836 ||| NN
pressure  ||| S:836 E:845 ||| NN
values ||| S:845 E:851 ||| NNS
.  ||| S:851 E:853 ||| .
Cardiovascular  ||| S:853 E:868 ||| JJ
risk  ||| S:868 E:873 ||| NN
was  ||| S:873 E:877 ||| VBD
stratified  ||| S:877 E:888 ||| VBN
according  ||| S:888 E:898 ||| VBG
to  ||| S:898 E:901 ||| TO
the  ||| S:901 E:905 ||| DT
2007  ||| S:905 E:910 ||| CD
ESC-ESH  ||| S:910 E:918 ||| JJ
guidelines ||| S:918 E:928 ||| NNS
.  ||| S:928 E:930 ||| .
The  ||| S:930 E:934 ||| DT
study  ||| S:934 E:940 ||| NN
sample  ||| S:940 E:947 ||| NN
comprised  ||| S:947 E:957 ||| NN
of  ||| S:957 E:960 ||| IN
903  ||| S:960 E:964 ||| CD
women  ||| S:964 E:970 ||| NNS
with  ||| S:970 E:975 ||| IN
a  ||| S:975 E:977 ||| DT
mean  ||| S:977 E:982 ||| JJ
age  ||| S:982 E:986 ||| NN
of  ||| S:986 E:989 ||| IN
59.6  ||| S:989 E:994 ||| CD
Â±  ||| S:994 E:996 ||| CD
8  ||| S:996 E:998 ||| CD
years ||| S:998 E:1003 ||| NNS
.  ||| S:1003 E:1005 ||| .
The  ||| S:1005 E:1009 ||| DT
prevalence  ||| S:1009 E:1020 ||| NN
of  ||| S:1020 E:1023 ||| IN
hypertension ||| S:1023 E:1035 ||| NN
,  ||| S:1035 E:1037 ||| ,
Type  ||| S:1037 E:1042 ||| NNP
2  ||| S:1042 E:1044 ||| CD
diabetes  ||| S:1044 E:1053 ||| NN
and  ||| S:1053 E:1057 ||| CC
dyslipidaemia  ||| S:1057 E:1071 ||| NNS
was  ||| S:1071 E:1075 ||| VBD
45.6 ||| S:1075 E:1079 ||| CD
,  ||| S:1079 E:1081 ||| ,
13.3  ||| S:1081 E:1086 ||| NNP
and  ||| S:1086 E:1090 ||| CC
41.7 ||| S:1090 E:1094 ||| CD
% ||| S:1094 E:1095 ||| NN
,  ||| S:1095 E:1097 ||| ,
respectively ||| S:1097 E:1109 ||| RB
.  ||| S:1109 E:1111 ||| .
Target  ||| S:1111 E:1118 ||| NN
organ  ||| S:1118 E:1124 ||| NN
damage  ||| S:1124 E:1131 ||| NN
affected  ||| S:1131 E:1140 ||| VBD
17.6 ||| S:1140 E:1144 ||| CD
%  ||| S:1144 E:1146 ||| NN
of  ||| S:1146 E:1149 ||| IN
women  ||| S:1149 E:1155 ||| NNS
and  ||| S:1155 E:1159 ||| CC
manifested  ||| S:1159 E:1170 ||| NN
as  ||| S:1170 E:1173 ||| IN
microalbuminuria  ||| S:1173 E:1190 ||| NNS
( ||| S:1190 E:1191 ||| -LRB-
1.8 ||| S:1191 E:1194 ||| CD
% ||| S:1194 E:1195 ||| NN
) ||| S:1195 E:1196 ||| -RRB-
,  ||| S:1196 E:1198 ||| ,
slight  ||| S:1198 E:1205 ||| JJ
increase  ||| S:1205 E:1214 ||| NN
in  ||| S:1214 E:1217 ||| IN
plasma  ||| S:1217 E:1224 ||| JJ
creatinine  ||| S:1224 E:1235 ||| NNS
( ||| S:1235 E:1236 ||| -LRB-
1.6 ||| S:1236 E:1239 ||| CD
% ||| S:1239 E:1240 ||| NN
)  ||| S:1240 E:1242 ||| -RRB-
and  ||| S:1242 E:1246 ||| CC
left  ||| S:1246 E:1251 ||| VBD
ventricular  ||| S:1251 E:1263 ||| JJ
hypertrophy  ||| S:1263 E:1275 ||| NNS
( ||| S:1275 E:1276 ||| -LRB-
2.9 ||| S:1276 E:1279 ||| CD
% ||| S:1279 E:1280 ||| NN
) ||| S:1280 E:1281 ||| -RRB-
.  ||| S:1281 E:1283 ||| .
Overall ||| S:1283 E:1290 ||| RB
,  ||| S:1290 E:1292 ||| ,
9.3 ||| S:1292 E:1295 ||| CD
%  ||| S:1295 E:1297 ||| NN
had  ||| S:1297 E:1301 ||| VBD
cardiovascular  ||| S:1301 E:1316 ||| JJ
disease ||| S:1316 E:1323 ||| NN
,  ||| S:1323 E:1325 ||| ,
3.4 ||| S:1325 E:1328 ||| CD
%  ||| S:1328 E:1330 ||| NN
coronary  ||| S:1330 E:1339 ||| NN
heart  ||| S:1339 E:1345 ||| NN
disease ||| S:1345 E:1352 ||| NN
,  ||| S:1352 E:1354 ||| ,
1.8 ||| S:1354 E:1357 ||| CD
%  ||| S:1357 E:1359 ||| NN
heart  ||| S:1359 E:1365 ||| NN
failure ||| S:1365 E:1372 ||| NN
,  ||| S:1372 E:1374 ||| ,
1.8 ||| S:1374 E:1377 ||| CD
%  ||| S:1377 E:1379 ||| NN
peripheral  ||| S:1379 E:1390 ||| JJ
artery  ||| S:1390 E:1397 ||| NN
disease  ||| S:1397 E:1405 ||| NN
and  ||| S:1405 E:1409 ||| CC
1.4 ||| S:1409 E:1412 ||| CD
%  ||| S:1412 E:1414 ||| NN
renal  ||| S:1414 E:1420 ||| JJ
disease ||| S:1420 E:1427 ||| NN
;  ||| S:1427 E:1429 ||| :
2.2 ||| S:1429 E:1432 ||| CD
%  ||| S:1432 E:1434 ||| NN
of  ||| S:1434 E:1437 ||| IN
patients  ||| S:1437 E:1446 ||| NNS
had  ||| S:1446 E:1450 ||| VBD
experienced  ||| S:1450 E:1462 ||| VBN
a  ||| S:1462 E:1464 ||| DT
stroke ||| S:1464 E:1470 ||| NN
.  ||| S:1470 E:1472 ||| .
The  ||| S:1472 E:1476 ||| DT
prevalence  ||| S:1476 E:1487 ||| NN
of  ||| S:1487 E:1490 ||| IN
cardiovascular  ||| S:1490 E:1505 ||| JJ
risk  ||| S:1505 E:1510 ||| NN
factors  ||| S:1510 E:1518 ||| NNS
in  ||| S:1518 E:1521 ||| IN
hypertensive  ||| S:1521 E:1534 ||| JJ
women  ||| S:1534 E:1540 ||| NNS
( ||| S:1540 E:1541 ||| -LRB-
HT ||| S:1541 E:1543 ||| NNP
)  ||| S:1543 E:1545 ||| -RRB-
with  ||| S:1545 E:1550 ||| IN
respect  ||| S:1550 E:1558 ||| NN
to  ||| S:1558 E:1561 ||| TO
non-hypertensive  ||| S:1561 E:1578 ||| JJ
women  ||| S:1578 E:1584 ||| NNS
( ||| S:1584 E:1585 ||| -LRB-
NHT ||| S:1585 E:1588 ||| NNP
)  ||| S:1588 E:1590 ||| -RRB-
was  ||| S:1590 E:1594 ||| VBD
as  ||| S:1594 E:1597 ||| RB
follows ||| S:1597 E:1604 ||| VBZ
:  ||| S:1604 E:1606 ||| :
obesity  ||| S:1606 E:1614 ||| CD
44.7  ||| S:1614 E:1619 ||| CD
versus  ||| S:1619 E:1626 ||| CD
18.9 ||| S:1626 E:1630 ||| CD
% ||| S:1630 E:1631 ||| NN
,  ||| S:1631 E:1633 ||| ,
dyslipidaemia  ||| S:1633 E:1647 ||| FW
48.8  ||| S:1647 E:1652 ||| FW
versus  ||| S:1652 E:1659 ||| FW
35.8 ||| S:1659 E:1663 ||| FW
%  ||| S:1663 E:1665 ||| NN
and  ||| S:1665 E:1669 ||| CC
Type  ||| S:1669 E:1674 ||| NNP
2  ||| S:1674 E:1676 ||| CD
diabetes  ||| S:1676 E:1685 ||| CD
21.8  ||| S:1685 E:1690 ||| CD
versus  ||| S:1690 E:1697 ||| CD
6.1 ||| S:1697 E:1700 ||| CD
% ||| S:1700 E:1701 ||| NN
.  ||| S:1701 E:1703 ||| .
The  ||| S:1703 E:1707 ||| DT
target  ||| S:1707 E:1714 ||| NN
organ  ||| S:1714 E:1720 ||| NN
damage  ||| S:1720 E:1727 ||| NN
was  ||| S:1727 E:1731 ||| VBD
more  ||| S:1731 E:1736 ||| RBR
prevalent  ||| S:1736 E:1746 ||| JJ
in  ||| S:1746 E:1749 ||| IN
hypertensive  ||| S:1749 E:1762 ||| JJ
women ||| S:1762 E:1767 ||| NNS
:  ||| S:1767 E:1769 ||| :
27.3  ||| S:1769 E:1774 ||| CD
versus  ||| S:1774 E:1781 ||| CD
9.4 ||| S:1781 E:1784 ||| CD
% ||| S:1784 E:1785 ||| NN
.  ||| S:1785 E:1787 ||| .
Cardiovascular  ||| S:1787 E:1802 ||| JJ
disease  ||| S:1802 E:1810 ||| NN
was  ||| S:1810 E:1814 ||| VBD
present  ||| S:1814 E:1822 ||| JJ
in  ||| S:1822 E:1825 ||| IN
14.8 ||| S:1825 E:1829 ||| CD
%  ||| S:1829 E:1831 ||| NN
of  ||| S:1831 E:1834 ||| IN
HT  ||| S:1834 E:1837 ||| NNP
and  ||| S:1837 E:1841 ||| CC
4.7 ||| S:1841 E:1844 ||| CD
%  ||| S:1844 E:1846 ||| NN
of  ||| S:1846 E:1849 ||| IN
NHT ||| S:1849 E:1852 ||| NNP
.  ||| S:1852 E:1854 ||| .
High  ||| S:1854 E:1859 ||| JJ
or  ||| S:1859 E:1862 ||| CC
very  ||| S:1862 E:1867 ||| RB
high  ||| S:1867 E:1872 ||| JJ
cardiovascular  ||| S:1872 E:1887 ||| JJ
risk  ||| S:1887 E:1892 ||| NN
affected  ||| S:1892 E:1901 ||| VBD
65.3 ||| S:1901 E:1905 ||| CD
%  ||| S:1905 E:1907 ||| NN
of  ||| S:1907 E:1910 ||| IN
HT  ||| S:1910 E:1913 ||| NNP
and  ||| S:1913 E:1917 ||| CC
26.9 ||| S:1917 E:1921 ||| CD
%  ||| S:1921 E:1923 ||| NN
of  ||| S:1923 E:1926 ||| IN
NHT ||| S:1926 E:1929 ||| NNP
.  ||| S:1929 E:1931 ||| .
Four  ||| S:1931 E:1936 ||| CD
in  ||| S:1936 E:1939 ||| IN
10  ||| S:1939 E:1942 ||| CD
women  ||| S:1942 E:1948 ||| NNS
attending  ||| S:1948 E:1958 ||| VBG
primary  ||| S:1958 E:1966 ||| JJ
care  ||| S:1966 E:1971 ||| NN
centres  ||| S:1971 E:1979 ||| NNS
had  ||| S:1979 E:1983 ||| VBD
a  ||| S:1983 E:1985 ||| DT
high  ||| S:1985 E:1990 ||| JJ
or  ||| S:1990 E:1993 ||| CC
very  ||| S:1993 E:1998 ||| RB
high  ||| S:1998 E:2003 ||| JJ
cardiovascular  ||| S:2003 E:2018 ||| JJ
risk ||| S:2018 E:2022 ||| NN
.  ||| S:2022 E:2024 ||| .
Percentages  ||| S:2024 E:2036 ||| NNS
of  ||| S:2036 E:2039 ||| IN
classic  ||| S:2039 E:2047 ||| JJ
cardiovascular  ||| S:2047 E:2062 ||| JJ
risk  ||| S:2062 E:2067 ||| NN
factors  ||| S:2067 E:2075 ||| NNS
were  ||| S:2075 E:2080 ||| VBD
higher  ||| S:2080 E:2087 ||| JJR
in  ||| S:2087 E:2090 ||| IN
HT  ||| S:2090 E:2093 ||| NNP
than  ||| S:2093 E:2098 ||| IN
in  ||| S:2098 E:2101 ||| IN
NHT  ||| S:2101 E:2105 ||| NNP
and  ||| S:2105 E:2109 ||| CC
increased  ||| S:2109 E:2119 ||| VBD
significantly  ||| S:2119 E:2133 ||| RB
with  ||| S:2133 E:2138 ||| IN
age ||| S:2138 E:2141 ||| NN
.  ||| S:2141 E:2143 ||| .
The  ||| S:2143 E:2147 ||| DT
most  ||| S:2147 E:2152 ||| RBS
commonly  ||| S:2152 E:2161 ||| RB
used  ||| S:2161 E:2166 ||| VBN
drugs  ||| S:2166 E:2172 ||| NNS
were  ||| S:2172 E:2177 ||| VBD
renin-angiotensin  ||| S:2177 E:2195 ||| JJ
system  ||| S:2195 E:2202 ||| NN
blockers  ||| S:2202 E:2211 ||| NNS
and  ||| S:2211 E:2215 ||| CC
diuretics ||| S:2215 E:2224 ||| NN
.  ||| S:2224 E:2226 ||| .
